On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB-IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results